Drug intelligence / Profile preview

hPLTs-01

Development stage: Preclinical
Lead developer: HemaCell Therapeutics
Modality: Stem Cell Therapies → Cell Therapies
Administration: Intravenous

Overview

hPLTs-01 (also known as hPLTs-01 A-type) is a preclinical-stage cell therapy being developed by **HemaCell Therapeutics** (Suzhou Xueji Biotechnology Co., Ltd.) for the treatment of **thrombocytopenia**. The therapy consists of functional platelets derived from hematopoietic stem and progenitor cells (HSPCs) using proprietary stem cell reprogramming, editing, and differentiation technologies. Unlike traditional platelet transfusions that rely on human donors, hPLTs-01 is an *in vitro* generated product designed to restore platelet counts and hemostatic function in patients with low platelet levels. This approach aims to provide a scalable and potentially safer alternative to donor-derived blood products.

Other names: hPLTs-01 A-typehPLTs01 A-typehPLTs 01 A-type

Beyond the preview

Go deeper on hPLTs-01.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on hPLTs-01.

Explore the full profile